NOVARTIS AG

NOVN
Real-time Estimate Quote. Real-time Estimate  - 03/03 11:20:00 am
80.545CHF -0.49%

Press Release : Novartis delivered sales growth -5-

01/26/2021 | 01:01am
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            20.7    14.7                  20.9    19.2 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating income         3 501   3 462      1      2  15 416  14 112     9      13 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            27.4    27.9                  31.7    29.7 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net income                    2 099   1 129     86     93   8 071   7 147    13      20 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
EPS (USD)                      0.92    0.50     84     93    3.55    3.12    14      21 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core net income               3 034   2 985      2      3  13 158  12 104     9      12 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core EPS (USD)                 1.34    1.32      2      3    5.78    5.28     9      13 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Cash flows from 
 operating activities         4 005   3 540     13         13 650  13 547     1 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Free cash flow                3 342   3 488     -4         11 691  12 937   -10 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Innovative Medicines           2020    2019    % change      2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net sales                    10 233   9 920      3      1  39 013  37 714     3       4 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Operating income              2 386   2 210      8     12   9 172   9 287    -1       4 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            23.3    22.3                  23.5    24.6 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating income         3 212   3 122      3      3  13 645  12 650     8      11 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            31.4    31.5                  35.0    33.5 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Sandoz                         2020    2019     % change     2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net sales                     2 537   2 483      2      0   9 646   9 731    -1       0 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Operating income                372    -195     nm     nm   1 043     551    89     106 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            14.7    -7.9                  10.8     5.7 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating income           528     517      2      3   2 334   2 094    11      15 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales            20.8    20.8                  24.2    21.5 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Corporate                      2020    2019    % change      2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Operating loss                 -114    -192     41     45     -63    -752    nm      nm 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating loss            -239    -177    -35    -28    -563    -632    11      14 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Discontinued operations        2020    2019    % change      2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net sales                                                           1 777 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Operating income                                                       71 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales                                                   4.0 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core operating income                                                 350 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
    As a % of sales                                                  19.7 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net Income                                                          4 590 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
                                 Q4      Q4                    FY      FY 
Total Group                    2020    2019    % change      2020    2019    % change 
                              USD m   USD m    USD     cc   USD m   USD m   USD      cc 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Net income                    2 099   1 129     86     93   8 071  11 737   -31     -27 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
EPS (USD)                      0.92    0.50     84     93    3.55    5.12   -31     -26 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core net income               3 034   2 985      2      3  13 158  12 382     6       9 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Core EPS (USD)                 1.34    1.32      2      3    5.78    5.40     7      10 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Cash flows 
 from operating activities    4 005   3 540     13         13 650  13 625     0 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
Free cash flow                3 342   3 488     -4         11 691  12 875    -9 
---------------------------  ------  ------  -----  -----  ------  ------  ----  ------ 
 
nm = not meaningful 
 
   (1) Continuing operations include the businesses of Innovative Medicines 
and Sandoz Division as well as the continuing corporate functions and 
discontinued operations include the business of Alcon. See page 43 of 
the Condensed Financial Report for full explanation. 
 
   (2) Constant currencies (cc), core results and free cash flow are 
non-IFRS measures. An explanation of non-IFRS measures can be found on 
page 55 of the Condensed Financial Report. Unless otherwise noted, all 
growth rates in this Release refer to same period in prior year. 
 
   Detailed financial results accompanying this press release are included 
in the Condensed Financial Report at the link below: 
 
   https://ml-eu.globenewswire.com/resource/download/62b8c900-3637-4459-a7a1-da6012d415b5/ 
 
 
   Disclaimer 
 
   This press release contains forward-looking statements within the 
meaning of the United States Private Securities Litigation Reform Act of 
1995, that can generally be identified by words such as "next wave," 
"transformative," "continuing," "progressing," "guidance," "will result, 
" "looking ahead," "confident," "progress," "to execute," "continue," 
"expect," "remains," "to maintain," "continues," "to evolve," "to take," 
"to help," "remain," "remains," "to grow," "continues," "to evolve," 
"continue," "to help," "remain," "to meet," "ongoing," "allowing," 
"launch," "addresses," "to work," "undertaking," "to develop," 
"investigating," "growing," "growth," "to support," "expected," "to be," 
"assume," "would," "estimates," "to advance," "to solidify," "committed, 
" "enabling" "to progress," "allowing," "anticipate," "pipelines," "to 
supplement," "investigational," "taking," "will," "estimated," "impact," 
"submissions," "focus," "launches," "innovation," "potential," "pipeline, 
" "priority," "outlook," "unforeseen," "forecast," "prevail," "enter," 
"to improve," "transformative," "manageable disruptions," "ongoing 
disruptions," "to delay," or similar expressions, or by express or 
implied discussions regarding potential new products, potential new 
indications for existing products, potential product launches, or 
regarding potential future revenues from any such products; or regarding 
the impact of the COVID-19 pandemic on certain therapeutic areas 
including dermatology, ophthalmology and the Sandoz retail business, and 
on drug development operations; or regarding potential future, pending 
or announced transactions; regarding potential future sales or earnings 
of the Group or any of its divisions; or by discussions of strategy, 
plans, expectations or intentions; or regarding the Group's liquidity or 

(MORE TO FOLLOW) Dow Jones Newswires

January 26, 2021 01:00 ET (06:00 GMT)

Copier lien
All news about NOVARTIS AG
7h ago
18h ago
18h ago
21h ago
1d ago